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Background: Targeted therapies have improved therapeutic options of treating renal cell carcinoma (RCC).
However, drug response is temporary due to resistance development.
Methods: Functional and molecular changes in RCC Caki-1 cells, after acquired resistance to the mammalian target
of rapamycin (mTOR)-inhibitor everolimus (Cakires), were investigated with and without additional application of the
histone deacetylase (HDAC)-inhibitor valproic acid (VPA). Cell growth was evaluated by MTT assay, cell cycle
progression and apoptosis by flow cytometry. Target molecules of everolimus and VPA, apoptotic and cell cycle
regulating proteins were investigated by western blotting. siRNA blockade was performed to evaluate the functional
relevance of the proteins.
Results: Everolimus resistance was accompanied by significant increases in the percentage of G2/M-phase cells
and in the IC50. Akt and p70S6K, targets of everolimus, were activated in Caki
res compared to drug sensitive cells.
The most prominent change in Cakires cells was an increase in the cell cycle activating proteins cdk2 and cyclin A.
Knock-down of cdk2 and cyclin A caused significant growth inhibition in the Cakires cells. The HDAC-inhibitor,
VPA, counteracted everolimus resistance in Cakires, evidenced by a significant decrease in tumor growth and
cdk2/cyclin A.
Conclusion: It is concluded that non-response to everolimus is characterized by increased cdk2/cyclin A, driving
RCC cells into the G2/M-phase. VPA hinders everolimus non-response by diminishing cdk2/cyclin A. Therefore,
treatment with HDAC-inhibitors might be an option for patients with advanced renal cell carcinoma and acquired
everolimus resistance.
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Over the past years the therapy for renal cell carcinoma
(RCC) has undergone change, with better understanding
of the molecular biology of RCC leading to the devel-
opment of several targeted agents. The phosphatidyl-
inositol-3 kinase (PI3K)/Akt/mammalian target of
rapamycin (mTOR) pathway has been identified as a* Correspondence: blaheta@em.uni-frankfurt.de
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unless otherwise stated.pivotal key regulator. mTOR has an impact on various
cellular functions, including cell growth, proliferation
and cell survival [1]. Two mTOR-inhibitors, temsiroli-
mus (Torisel®) and everolimus (Afinitor®), have been
approved by the FDA to treat advanced RCC due to
prolonged progression free survival [2-4]. However,
targeted therapy is not curative in metastatic RCC and
drug response is limited. Recently, it has been shown
that chronic mTOR-inhibition evokes undesired feed-
back mechanisms in RCC cells, which may lead to re-
sistance development [5,6]. Undesirable feedback has
also been demonstrated in prostate cancer cells afterl Ltd. This is an Open Access article distributed under the terms of the Creative
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http://www.molecular-cancer.com/content/13/1/152chronic exposure to everolimus, indicating molecular
alterations tied to acquired resistance [7]. Agents tar-
geting such feedback loops and cross talk with other
pathways involved in acquired resistance to mTOR-
inhibition are, therefore, urgently required [8]. Studies
and clinical trials have demonstrated that histone dea-
cetylase (HDAC)-inhibitors in combination with other
therapies, including targeted therapies, induce syner-
gistic or additive anti-tumor effects [9-11]. It has also
been reported that during chronic application of evero-
limus, combination with the HDAC-inhibitor valproic
acid (VPA) contributes to sustained anti-tumor activity
[6]. Additionally, HDAC-inhibitors have been shown to
re-sensitize tumor cells to cytotoxic drug treatment
[12,13]. Hence, HDAC-inhibition might prove promis-
ing in reversing everolimus resistance in RCC. To fol-
low up on a pilot study employing everolimus resistant
RCC Caki-1 cells (Cakires) [6], resistance dependent
functional and molecular aberrations were investigated
in the same cell line. Further investigation was designed to
determine whether Cakires cell growth could be influenced
by the HDAC-inhibitor VPA, whereby the growth behav-
ior of Cakires compared to VPA treated Cakires cells was
evaluated. It is shown that everolimus resistance contrib-
utes to a significant increase in the IC50, an elevated per-
centage of G2/M-phase cells and distinct up-regulation of
the cell cycle activating proteins cdk2 and cyclin A. VPA
counteracted everolimus resistance by significantly inhibit-
ing tumor growth and reducing cdk2 and cyclin A. Thus,
VPA might represent a new promising treatment option
for RCC patients with acquired everolimus resistance.
Results
Exposure to everolimus induced resistance in RCC cells
24 h exposure to ascending concentrations of everolimus
[0.1-1 μM] induced a dose dependent significant reduc-
tion in the number of Cakipar cells compared to the un-
treated control (set to 100%, Figure 1A) with an IC50 ofFigure 1 Dose response analysis of Cakipar and Cakires. (A) Growth effi
cell growth from 24 h to 72 h. *Indicates significant difference to controls,
were calculated from dose response analysis. (B) Cell cycle analysis of unsy
cell cultures. The cell phase is expressed as percentage of total cells. The fig0.78 ± 0.23 nM. Everolimus resistance (Cakires) was ev-
idenced by a significant shift of the IC50 to 10.47 ±
3.14 nM.
Resistance towards everolimus significantly enhanced the
G2/M-phase
Evaluation of cell cycle progression revealed significant
alterations after acquired everolimus resistance. The G2/
M-phase percentage was increased in unsynchronized
Cakires cells, compared to Cakipar, and was accompanied
by a decrease in the S-phase (Figure 1B). Synchronization
of the cells led to a similar shift, additionally reducing the
percentage of G0/G1-phase cells in Cakires (Figure 1B).
Re-treatment of Cakires with therapeutic everolimus
concentrations caused an increase in the G2/M-phase
Treatment of Cakipar for 24 h with 1, 5 or 50 nM everoli-
mus dose-dependently reduced S- and G2/M-phase
cells, while the percentage of G0/G1-phase cells increased
(Figure 2A). Re-treatment with everolimus had no signifi-
cant effect on any cell phase in Cakires, regardless of
the concentration (Figure 2B). Therefore, all further
re-treatment investigation was performed with 1 nM
everolimus.
Resistance-dependent alteration in tumor growth was
associated with modulated protein expression
After 24 h exposure to 1 nM everolimus, Cakipar revealed
a decrease in phosphorylated Akt (pAkt) and p70S6 kinase
(pp70S6K) compared to untreated Cakipar (Figure 3). Con-
comitantly, Akt’s negative regulator PTEN (pPTEN) was
activated by 1 nM everolimus. The 24 h application of 1
nM everolimus to Cakipar caused a distinct decrease in the
cell cycle activating proteins cdk1 and cdk2 as well as in
cyclin A and cyclin B, whereas the negative cell cycle regu-
lator p27 was elevated. Compared to Cakipar, Cakires dis-
played an activation of pAkt and considerable elevation of
cdk1, cdk2, cdk4 and cyclin E, whereas p27, p53 and p73cacy of increasing concentrations of everolimus on Cakipar and Cakires
set to 100% (SD≤ 16%, n = 6). IC50-values of Caki
par and Cakires cells
nchronized and synchronized Cakipar and Cakires cells in subconfluent
ure shows one of five separate experiments.
Figure 2 Cell cycle analysis of Cakipar (A) and Cakires (B) after 24 h exposure to 1, 5 and 50 nM everolimus in subconfluent cell
cultures. The cell population is expressed as percentage of the total cells analyzed. Untreated cells served as controls. One representative
experiment of six is shown.
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mus evoked additional activation of pAkt and pp70S6K, a
further augmentation of cdk2 and cyclin A, along with de-
activation of pPTEN. However, the expression of p27, p53
and p73 was elevated in Cakires after re-treatment.
The HDAC-inhibitor VPA inhibited tumor growth in
Cakipar and Cakires
Application of the HDAC-inhibitor VPA [1 mM] to
Cakipar cells for 1 or 2 weeks contributed to a significant
reduction in cell growth (Figure 4A,B), although to a
lesser extent than that from 1 nM everolimus exposure.
Exposing Cakires to VPA [1 mM] also led to significantly
diminished tumor growth (Figure 4A,B). The VPA in-
duced growth inhibition in Cakires was significantly higher
than that in Cakipar.
Resistance-dependent alterations in protein expression
were counteracted by HDAC-inhibition through VPA
VPA caused deactivation of pAkt and pp70S6k in Cakires
after 1 or 2 weeks (Figure 5A). In addition, the expres-
sion of Akt and p70S6k was diminished with VPA after
1 week. In contrast, the activity of pPTEN was enhanced
after 1 or 2 weeks of VPA treatment, compared to un-
treated Cakires. Applying VPA for 1 or 2 weeks to Cakires
caused a considerable decrease in cdk2 and cyclin A and
an elevation in p27 (Figure 5A). VPA treatment resulted
in increased acetylation (1 or 2 weeks) and increased
total content of histone H3 and H4 (2 weeks) in Cakires
(Figure 5B).
Resistance towards everolimus did not affect apoptosis in
RCC
Apoptosis was not influenced by treatment with everoli-
mus in either Cakipar or Cakires (data not shown). In
good accordance, examination of the apoptosis proteins
caspase 3 and PARP by western blot showed no differ-
ences between Cakipar and Cakires and no changes were
apparent after treatment with VPA (data not shown).siRNA knock-down
Since cdk2 and cyclin A were distinctly increased in
RCCres and were mainly affected by VPA treatment,
their functional relevance during resistance dependent
tumor growth was evaluated by siRNA knock-down.
Cdk2 and cyclin A siRNA blockade, verified by western
blot analysis (Figure 6A), resulted in significant growth
inhibition in both Cakipar and Cakires, compared to un-
treated and siRNA controls (Figure 7A + B left). The im-
pact of HDAC1 and HDAC2 as targets of VPA was also
determined by siRNA blockade. HDAC1 and HDAC2
siRNA knock-down contributed to an increase in histone
H3 and H4 acetylation in Cakipar and Cakires (Figure 6B).
The observed elevation of histone H3 and H4 acetylation
was accompanied by significantly reduced tumor growth
in Cakipar and Cakires, compared to untreated and siRNA
controls (Figure 7A + B right).Discussion
Chronic everolimus treatment led to drug resistant RCC
cells. It was possible to hinder resistance by applying the
HDAC-inhibitor VPA.
Cakires revealed a 13-fold higher IC50 than Caki
par.
This IC50 change is within the range of the 4 to 22 fold-
change used to define drug-resistance [14,15], indicating
clear-cut everolimus resistance. The IC50 shift was asso-
ciated with a considerable increase in the G2/M-phase,
whereby S-phase cells were shifted into the G2/M-phase
and the G0/G1-phase fraction was reduced. Such a shift
has also been observed during lung cancer drug resist-
ance with an accelerated G2/M-phase transition [16]. In
prostate cancer cells everolimus resistance has also re-
vealed a higher G2/M-phase cell cycle fraction [7]. Based
on a recent study, chronic everolimus application to
RCC cells resulted in an accumulation of G2/M-phase
cells [6]. The G2/M-shift may, therefore, be characteris-
tic of chronic everolimus exposure and be associated
with resistance development.
Figure 3 Western blot analysis of cell cycle regulating proteins
and everolimus target molecules. Cakipar and Cakires treated with
1 nM everolimus for 24 h. Controls remained untreated. β-actin
served as the internal control. The figure shows one representative
from three separate experiments.
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molecular changes, including activation of the everolimus
target molecules Akt and p70S6K. Re-treatment of Cakires
with 1 nM everolimus evoked additional activation of Aktand p70S6k, whereas the activity of the Akt negative regu-
lator, PTEN, was diminished. Akt is a key molecule with
multiple functions, including cell growth and survival.
Tumor progression and resistance development in RCC
in vitro and in vivo towards different agents has been as-
sociated with increased activity of the PI3K/Akt/mTOR
signaling pathway [5,8,17,18]. Enhanced activity of Akt
has also been shown to be involved in bone metastasis,
larger tumor size, grades III/IV tumors and shorter
disease-free survival in RCC [19-21]. Moreover, elevated
Akt phosphorylation has been associated with hyperproli-
feration and overexpression of cell cycle proteins [22]. In-
deed, the present study shows that the cell cycle activating
proteins cdk2 and cyclin A were both over-expressed in
Cakires compared to Cakipar, and further increased after
re-treatment with everolimus. The finding that proteins
involved in mitotic control were further up-regulated after
applying a therapeutic everolimus concentration is clinic-
ally relevant, since mitotic activity of tumor cells is often
accelerated, once resistance has developed. In the present
investigation the number of mitotic cells significantly in-
creased when Cakires cells were exposed to low-dosed
everolimus. This finding might, therefore, explain why
RCC patients, treated with temsirolimus or everolimus
often develop progressive disease [23]. The same pro-
gression has been observed in different gynecologic can-
cers as well as estrogen receptor-positive breast cancer
and colorectal carcinoma, indicating a correlation be-
tween treatment resistance and enhanced aggressiveness
characterized by accelerated tumor growth [24-26].
The functional relevance of cdk2 and cyclin A in
tumor growth was verified by siRNA knock down, re-
vealing significant growth inhibition after cdk2 and cyc-
lin A loss. Cdk2 and cyclin A establish complexes in the
S-phase and are required for entrance into the G2/M-
phase. Indeed, low expression of cdk2 and cyclin A has
been shown to be associated with cell cycle arrest and
accumulation of cells in the S-phase [27]. Everolimus re-
sistance has also been associated with a considerable in-
crease in cdk2 in prostate cancer [7] and in RCC cells
[6]. Thus, augmented cdk2 seems closely related to non-
responsiveness towards everolimus and deserves atten-
tion in overcoming resistance development. High levels
of cyclin A have been associated with a worse outcome
and have been proposed as a prognostic factor in breast
cancer, as well [28-30]. Similarly, a cyclin A increase in
RCC has been associated with elevated tumor size and
poor survival [31]. In good accordance with the present
findings regarding Cakires, cyclin A expression has been
shown to be inversely correlated with the expression of
the cell cycle negative regulator p27 in RCC [31]. It may,
therefore, be concluded that resistance development to-
wards everolimus is accompanied by elevated cdk2/cyc-
lin A, driving tumor cells from the S- into the G2/M-
Figure 4 Cell growth analysis. Growth inhibitory efficacy of 1 nM or 1 mM VPA in Cakipar and Cakires cells treated for one (A) or two weeks (B).
*Indicates significant difference to untreated controls, set at 100%. #Indicates significant difference between Cakipar + VPA and Cakires + VPA
(SD≤ 22%, n = 6).
Figure 5 Western blot analysis of Cakires exposed to 1 mM VPA for one (1 wk) or two weeks (2 wks) showing cell cycle regulating
proteins and target molecules of mTOR- (A) and HDAC-inhibitors (B). VPA untreated cells served as controls. β-actin served as the internal
control. The figure shows one representative from three separate experiments.
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Figure 6 siRNA knock-down controls. siRNA blockade of cdk2 or cyclin A (A) and HDAC1 or HDAC2 (B) were confirmed by western blotting.
Cakipar and Cakires cells were transfected with cdk2, cyclin A, HDAC1 or HDAC2 siRNA. Untreated cells and with control siRNA transfected cells
served as controls. One representative from three experiments is shown.
Juengel et al. Molecular Cancer 2014, 13:152 Page 6 of 10
http://www.molecular-cancer.com/content/13/1/152phase, leading to a more aggressive tumor phenotype
with enhanced growth capacity.
The HDAC-inhibitor VPA caused a significant decrease
in RCC tumor growth. Since VPA’s growth inhibitory ef-
fect on Caki-1 was even more pronounced in Cakires than
in Cakipar, VPA seems to re-sensitize the tumor cells to
everolimus. However, it may also be concluded that
chronic treatment with everolimus sensitizes the cells to
VPA treatment. Although this is speculative, various
studies have shown that HDAC-inhibitors in combin-
ation with everolimus induce synergistic anti-tumor ef-
fects [10]. HDAC-inhibitors have been implicated in the
re-sensitization of tumor cells to cytotoxic drug treat-
ment [12,13] and concomitant application of VPA with
chemo- or targeted therapies has shown that VPA pre-
vents tumor cells from becoming resistant [6,32]. VPA
may, therefore, counteract resistance dependent feed-
back loops and reverse molecular alterations in everolimus
resistant cells. VPA treatment did deactivate proteins asso-
ciated with mitosis in the Cakires cells, particularly Akt
and p70S6k. Both cdk2 and cyclin A were stronglyenhanced in Cakires and were considerably reduced in the
presence of VPA. Thus, cdk2 and cyclin A could serve
as predictive indicators for a response to VPA. In several
tumor entities application of VPA for up to 2 weeks has
resulted in counter-regulation of the cdk-cyclin axis,
contributing to significant growth inhibition [6,33].
Since cdk2/cyclin A reduction and growth inhibition in
Cakires after application with VPA was accompanied by
acetylation of histone H3 and H4, epigenetic modifica-
tion might be involved in the anti-tumor effect. Other
investigators have also reported an association between
histone H3 and H4 acetylation, cdk2 reduction and di-
minished growth in bladder and prostate cancer cells
[33,34]. Knock-down of HDAC1 and HDAC2, respon-
sible for deacetylation of histone H3 and H4 [35,36], has
induced considerable acetylation of histone H3 and H4
in Cakires, correlating with significant growth inhibition.
The present investigation also indicates that histone H3
and H4 acetylation diminishes tumor growth, probably
by influencing the cell cycle activating proteins cdk2/
cyclin A.
Figure 7 Influence of cdk2, cyclin A, HDAC1 or HDAC2 knock-down on tumor cell growth. Cakipar (A) and Cakires (B) cells were transfected
with cdk2, cyclin A HDAC1 or HDAC2 siRNA and then subjected to the MTT cell growth assay. Untreated cells and with control siRNA transfected
cells served as controls. Cell number of control Cakipar or Cakires cells and the corresponding knock-down cells were measured. *Indicates
significant difference to untreated and siRNA controls (SD≤ 18%, n = 6).
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The present findings reveal that resistance development
towards the mTOR-inhibitor, everolimus, is associated
with undesired feedback loops, including activation of
the Akt/mTOR signaling pathway and increased cdk2/
cyclin A expression, and is associated with cell cycle pro-
gression and tumor growth. Evidence is provided that
re-treatment with everolimus not only fails to inhibit
tumor progression in Cakires, but activates progression.
Since resistance is a serious problem in treating RCC the
HDAC-inhibitor VPA could be employed to impair
cdk2/cyclin A expression. Acetylation of histone H3 and
H4 plays a pivotal role in this process, significantly inhibit-
ing tumor cell growth. Patients with renal cell carcinoma
and acquired everolimus resistance might, therefore, bene-
fit from treatment with VPA. In vivo investigation and
clinical trials are necessary to verify tumor growth inhib-
ition by VPA in everolimus resistant renal cell carcinoma.
Methods
Cell culture
Kidney carcinoma cells, Caki-1, were purchased from
LGC Promochem (Wesel, Germany). The cells were
grown and subcultured in RPMI 1640 medium (Seromed,
Berlin, Germany) supplemented with 10% FCS, 20 mMHepes-buffer, 100 IU/ml penicillin and 100 μg/ml strepto-
mycin at 37°C in a humidified, 5% CO2 incubator.Drugs
Everolimus (RAD001, Afinitor™, Novartis Pharma AG,
Basel, Switzerland) was dissolved in DMSO as a 10 mM
stock solution and stored as aliquots at -20°C. Prior to
experiments, everolimus was diluted in cell culture
medium. Resistance towards everolimus was induced by
treating Caki-1 cells with stepwise ascending concentra-
tions from 1 nM up to 1 μM. The tumor cells were fur-
ther exposed to 1 μM everolimus twice a week for over
one year. Tumor cells, resistant to everolimus, were des-
ignated Cakires and control cells, sensitive to everolimus,
were designated Cakipar.
Besides comparing characteristics of Cakires to Cakipar,
the response to therapeutic everolimus concentrations
(drug re-treatment) was also investigated. Preparation
for everolimus re-treatment was carried out by incubat-
ing Cakires cells for three days with everolimus-free
medium. Subsequently, 1, 5 or 50 nM everolimus was
applied to the Cakires and Cakipar cells.
Valproic acid (VPA) (G. L. Pharma GmbH, Lannach,
Austria) was applied at a final concentration of 1 mM to
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1 or 2 weeks. Control cell cultures remained untreated.
To evaluate toxic effects of applied drugs, cell viabil-
ity was determined by trypan blue (Gibco/Invitrogen,
Darmstadt, Germany).Apoptosis
To detect apoptosis the expression of Annexin V/propi-
dium iodide (PI) was evaluated using the Annexin V-FITC
Apoptosis Detection kit (BD Pharmingen, Heidelberg,
Germany). Tumor cells were washed twice with PBS-
buffer, and then incubated with 5 μl of Annexin V-FITC
and 5 μl of PI in the dark for 15 min at room temperature.
Cells were analyzed on a FACScalibur (BD Biosciences,
Heidelberg, Germany). The percentage of vital, necrotic
and apoptotic cells (early and late) in each quadrant was
calculated using Cell-Quest software (BD Biosciences).Measurement of tumor cell growth and proliferation
Cell growth was assessed using the 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
dye reduction assay (Roche Diagnostics, Penzberg,
Germany). RCC cells (50 μl, 1×105 cells/ml) were seeded
onto 96-well tissue culture plates. After 24, 48 and 72 h
MTT (0.5 mg/ml) was added for an additional 4 h.
Thereafter, cells were lysed in a buffer containing 10%
SDS in 0.01 M HCl. The plates were incubated overnight
at 37 °C, 5% CO2. Absorbance at 550 nm was deter-
mined for each well using a microplate ELISA reader.
Each experiment was done in triplicate. After subtract-
ing background absorbance, results were expressed as
mean cell number. IC50 values were calculated on the
basis of the dose response analysis of Cakipar and Cakires
using GraphPad Prism 5.0.Cell cycle analysis
Cell cycle analysis was performed with RCC cultures
grown to subconfluency and carried out after 24 h using
both asynchronous and synchronous cell populations.
Caki-1 cells were synchronized at the G1-S boundary
with aphidicolin (1 μg/ml) 24 h before starting cell cycle
analysis and subsequently resuspended in fresh (aphidi-
colin free) medium for 2 h. Asynchronous or synchron-
ous tumor cell populations were stained with propidium
iodide using a Cycle TEST PLUS DNA Reagent Kit (Becton
Dickinson) and then subjected to flow cytometry with a
FACScan flow cytometer (Becton Dickinson). 10,000 events
were collected from each sample. Data acquisition was car-
ried out using Cell-Quest software and cell cycle distribu-
tion, calculated with ModFit software (Becton Dickinson).
The number of gated cells in the G1-, S- or G2/M-phases
were expressed in%.Western blot analysis
To investigate cell cycle regulating proteins in Caki-1 cells,
tumor cell lysates (50 μg) were applied to polyacrylamide
gels (7-15%) and electrophoresed for 90 min at 100 V.
The protein was then transferred to nitrocellulose mem-
branes. After blocking with non-fat dry milk for 1 h, the
membranes were incubated overnight with monoclonal
antibodies directed against cell cycle proteins: cdk1
(mouse IgG1, clone 1, dilution 1:2,500), cdk2 (mouse
IgG2a, clone 55, dilution 1:2,500), cdk4 (mouse IgG1,
clone 97; dilution 1:250), cyclin A (mouse IgG1, clone 25,
dilution 1:250), cyclin B (mouse IgG1, clone 18, dilution
1:1,000), cyclin D1 (mouse IgG1, clone G124-326, dilution
1:250), cyclin E (mouse IgG1, clone HE12, dilution
1:1,000), p19 (mouse IgG1, clone 52/p19, 1:5,000), p21
(mouse IgG1, clone 2G12, dilution 1:250), p27 (Kip1,
mouse IgG1, clone 57, 1:500), p53 (mouse IgG2b, clone
DO-7, dilution 1:500) and p73 (mouse IgG1, clone ER-15,
dilution 1:500, all: BD Biosciences). Apoptotic effects, the
protein expression of caspase 3 and PARP (both: rabbit
IgG, dilution 1:1,000, Cell Signaling Technology by New
England Biolabs GmbH, Frankfurt, Germany) were also
investigated. To evaluate target specificity of everolimus
and VPA, mTOR signaling and histone acetylation were
evaluated. The following monoclonal antibodies were
employed to determine mTOR signaling: Akt (PKBα/Akt,
clone 55), phospho Akt (pAkt; clone 104A282, both:
mouse IgG1, dilution 1:500, BD Biosciences), p70S6k
(clone 49D7), phospho p70S6k (pp70S6k; clone 108D2),
PTEN (phosphatase and tensin homolog) and phospho
PTEN (Ser380/Thr382/383, all: rabbit IgG, dilution
1:1,000, Cell Signaling Technology). To investigate histone
acetylation, cell lysates were marked with anti-histone H3
(rabbit IgG, clone Y173, dilution 1:5,000), anti-acetylated
H3 (rabbit IgG, clone Y28, dilution 1:500, both: Epitomics,
USA), anti-histone H4 (rabbit IgG, clone: N/A, dilution
1:250, Imgenex, USA) and anti-acetylated H4 (Lys8, rabbit
IgG, dilution 1:500, Upstate Biotechnology, USA). HRP-
conjugated goat-anti-mouse or goat-anti-rabbit IgG (both:
dilution 1:5,000, Upstate Biotechnology, Lake Placid, NY,
USA) were used as secondary antibodies. The membranes
were briefly incubated with ECL detection reagent
(ECL™, Amersham/GE Healthcare, München, Germany)
to visualize the proteins and exposed to an x-ray-film
(Hyperfilm™ EC™; Amersham/GE Healthcare). β-actin
(dilution 1:1,000, Sigma, Taufenkirchen, Germany) served
as the internal control.
siRNA blockade
Caki-1 cells (3×105/6-well) were transfected with small
interfering RNA (siRNA) directed against cdk2 (gene ID:
1017, target sequence: AGGTGGTGGCGCTTAAGAA
AA), cyclin A (gene ID: 890, target sequence: GCCAG
CTGTCAGGATAATAAA), HDAC1 (gene ID: 3065,
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HDAC2 (gene ID: 3066, target sequence: TCCCAAT-
GAGTTGCCATATAA; all: Qiagen, Hilden, Germany)
with a siRNA/transfection reagent (HiPerFect Transfec-
tion Reagent; Qiagen, Hilden, Germany) ratio of 1:6.
Untreated cells and cells treated with 5 nM control
siRNA (All stars negative control siRNA; Qiagen, Hil-
den, Germany) served as controls. Knock-down was
verified by western blot analysis. Tumor cell growth was
analyzed by the MTT assay as indicated above.
Statistics
All experiments were performed 3-6 times. Statistical
significance was investigated by the Wilcoxon-Mann-
Whitney-U-test. Differences were considered statistically
significant at a p-value less than 0.05.
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